Neuraly Incis A Clinical Stage Biotechnology Company Based In Marylandit Specializes In Developing Therapeutics For Neurodegenerative Disordersincluding Parkinsonae S Diseasealzheimerae S Diseaseand Metabolic Dysfunction Associated Steatohepatitisas A Subsidiary Of D&D Pharmatech Inc Neuraly Collaborates With Institutions Like Johns Hopkins University School Of Medicineutilizing Research From Co Founder Drted Dawson On Glial Cell Biology And Neuroinflammation The Company S Research Focuses On Glial Cells And Their Role In Neuroinflammation And Neuroprotectionneuraly Has Several Products In Its Pipelineincluding Nly01A Candidate For Parkinsonae S Disease That Completed A Phase 2 Trial In 2023And Dd01A Therapy For Metabolic Disorders That Received Fda Fast Track Designation In March 2024Additionallypmi04 Is A Pet Imaging Biomarker For Neuroinflammationlicensed To Enigma Biomedical Usa For Further Developmentneuraly Emphasizes Risk Diversified Programs And Maintains Partnerships To Advance Its Clinical And Commercial Strategies
No conferences found for this company.
| Company Name | Neuraly Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
